Pesticide residue profiles in bee bread and pollen samples and the survival of honeybee colonies-a case study from Luxembourg.

Pesticide residues (112 compounds) were quantified by GC-MS/MS or LC-MS/MS in 85 bee bread samples and 154 pollen samples obtained from five apiaries each with three or four colonies (genotype Buckfast) in Luxembourg over the period 2011-2013. Thiacloprid, chlorfenvinphos, tebuconazole, and methiocarb were found most frequently in bee bread while thiacloprid, permethrin-cis, and permethrin-trans were detected most frequently in the pollen samples. Three neonicotinoid insecticides (clothianidin, imidacloprid, and thiamethoxam) that were restricted by an EU regulation in 2013 after our sampling campaign was finished were each found in less than 8% of the pollen or bee bread samples. The maximum concentrations of thiacloprid, metazachlor, and methiocarb measured in the pollen collected by a group of honeybee colonies (n = 5) without survivors within the 3-year period of observation were 86.20 ± 10.74 ng/g, 2.80 ± 1.26 ng/g, and below the limit of quantification, respectively. The maximum concentrations of the same compounds measured in the pollen collected by a group of honeybee colonies with significantly (P = 0.02) more survivors (7 out of 9) than expected, if the survivors had been distributed randomly among the groups of colonies, were 11.98 ± 2.28 ng/g, 0.44 ± 0.29 ng/g, and 8.49 ± 4.13 ng/g, respectively. No honeybee colony that gathered pollen containing more than 23 ng/g thiacloprid survived the 3-year project period. There was no statistically significant association between pesticide residues in the bee bread and the survival of the colonies. Actions already taken or planned and potential further actions to protect bees from exposure to pesticides are discussed.

Winter honey bee colony losses, Varroa destructor control strategies, and the role of weather conditions: Results from a survey among beekeepers.

Sets of treatments that were applied against varroa mites in the Luxembourgish beekeeper community were surveyed annually with a questionnaire between the winters 2010/11 and 2014/15. The average temperature and the precipitation sum of the month, when the respective varroa control method was applied were considered as co-variables when evaluating the efficacy of varroa control regimes. Success or failure of control regimes was evaluated based on the percentage of colonies lost per apiary in the winter following the treatment(s). Neither a positive nor a negative effect of formic acid (concentration 60%, w/v) on the colony losses could be found, irrespective of the weather conditions around the time of application. The higher concentration of 85% formic acid was linked with reduced colony losses when applications were done in August. Colony losses were reduced when Thymovar was applied in July or August, but applications in September were associated with increased losses compared with apiaries not treated with Thymovar during the same period. Apilife application in July as well as Apivar applications between July and September were associated with reduced colony losses. The removal of the drone brood and trickled oxalic acid application had beneficial effects when being done in April and December, respectively. Relatively warm (3.0±1.3°C) and wet (507.0±38.6mm/2months) conditions during the winter months December and January and relatively cool (17.2±1.4°C average monthly temperature) and wet (110.8±55.5mm/month) conditions in July were associated with elevated honey bee colony losses.

Correlations between land covers and honey bee colony losses in a country with industrialized and rural regions.

High levels of honey bee colony losses were recently reported from Canada, China, Europe, Israel, Turkey and the United States, raising concerns of a global pollinator decline and questioning current land use practices, in particular intense agricultural cropping systems. Sixty-seven crops (data from the years 2010-2012) and 66 mid-term stable land cover classes (data from 2007) were analysed for statistical relationships with the honey bee colony losses experienced over the winters 2010/11-2012/13 in Luxembourg (Western Europe). The area covered by each land cover class, the shortest distance between each land cover class and the respective apiary, the number of plots covered by each land use class and the size of the biggest plot of each land cover class within radii of 2 km and 5 km around 166 apiaries (2010), 184 apiaries (2011) and 188 apiaries (2012) were tested for correlations with honey bee colony losses (% per apiary) experienced in the winter following the season when the crops were grown. Artificial water bodies, open urban areas, large industrial facilities including heavy industry, railways and associated installations, buildings and installations with socio-cultural purpose, camping-, sports-, playgrounds, golf courts, oilseed crops other than oilseed rape like sunflower or linseed, some spring cereals and former forest clearcuts or windthrows were the land cover classes most frequently associated with high honey bee colony losses. Grain maize, mixed forest and mixed coniferous forest were the land cover classes most frequently associated with low honey bee colony losses. The present data suggest that land covers related to transport, industry and leisure may have made a more substantial contribution to winter honey bee colony losses in developed countries than anticipated so far. Recommendations for the positioning of apiaries are discussed.

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

CONTEXT: Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly. There are also limited data for the long-acting lanreotide formulation. OBJECTIVE: The aim of the study was to better characterize the effects of primary lanreotide Autogel treatment on tumor size in patients with GH-secreting macroadenomas. DESIGN: PRIMARYS was a 48-week, multicenter, open-label, single-arm study. SETTING: The study was conducted at specialist endocrine centers. PATIENTS: Treatment-naïve acromegalic patients with GH-secreting macroadenomas participated in the study. INTERVENTION: Lanreotide Autogel 120 mg was administered sc every 28 days (without dose titration). OUTCOME MEASURES: The primary endpoint was the proportion of patients with clinically significant (≥20%) tumor volume reduction (TVR) at week 48/last post-baseline value available using central assessments from three readers. The null hypothesis (H0) for the primary endpoint was that the proportion with TVR was ≤55%. Secondary endpoints included: TVR at other time points, GH and IGF-1, acromegalic symptoms, quality of life (QoL), and safety. RESULTS: Sixty-four of 90 (71.1%) patients completed the study. Clinically significant TVR at 48 weeks/last post-baseline value available was achieved by 62.9% (95% confidence interval, 52.0, 72.9) of 89 patients in the primary analysis (intention-to-treat population; H0 not rejected) and 71.9-75.3% in sensitivity (n = 89) and secondary analyses (n = 63) (H0 rejected). At 12 weeks, 54.1% had clinically significant TVR. Early and sustained improvements also occurred in GH and IGF-1, acromegalic symptoms, and QoL. No patients withdrew due to gastrointestinal intolerance. CONCLUSIONS: Primary treatment with lanreotide Autogel, administered at 120 mg (highest available dose) without dose titration, in patients with GH-secreting macroadenomas provides early and sustained reductions in tumor volume, GH and IGF-1, and acromegalic symptoms, and improves QoL.

Efficacy of 5-day cefpodoxime proxetil for recurrent pharyngitis in adults. A comparative study with 10-day penicillin V or amoxycillin---clavulanate.

OBJECTIVE: To compare the clinical and bacteriologic efficacy of a 5-day course of cefpodoxime proxetil (CPD) with that of a 10-day course of penicillin V (PNV) or amoxycillin---clavulanate (AMC) in recurrent pharyngitis in adults. A cost-effectiveness study (reported elsewhere) was carried out at the same time. METHODS: This multicenter, randomized, open label trial involved 580 adult patients consulting general practitioners for clinical recurrent pharyngitis (greater-than-or-equal3 episodes within the last 12 months) regardless of the bacterial etiology. Patients were treated for 5 days with CPD, 100 mg twice daily, or for 10 days with PNV, 1x106 IU three times a day, or for 10 days with AMC, 500 mg (amoxycillin) three times a day. Clinical and bacteriologic outcomes were noted at the end of treatment, and cases of clinical recurrence were recorded during a 6-month follow-up period. RESULTS: At the end of treatment, clinical response was satisfactory in 157 of 170 (92.3%) patients on CPD, 147 of 166 (88.5%) patients on PNV, and 168 of 177 (94.9%) patients on AMC. Group A beta-hemolytic streptococci (GABHS) were eradicated in 22 of 23 (95.65%) patients on CPD, 16 of 16 (100%) patients on PNV, and 19 of 20 (95%) patients on AMC. The rates of clinical success and GABHS eradication were not significantly different between the groups. Compliance (p<0.001) and tolerance (p<0.001) were significantly better in the CPD group than in the other two groups. Among the 389 patients evaluable 6 months after the end of treatment, the recurrence rate of acute pharyngitis (due to any bacterium) was significantly lower in the CPD group (p=0.01 versus PNV; p<0.01 versus AMC). A Kaplan---Meier analysis (469 patients over 6 months) of the rate of non-recurrence, with comparison by the log-rank test, also showed a significant difference in favor of CPD. CONCLUSIONS: A 5-day treatment of recurrent pharyngitis with CPD was as effective and better tolerated than a 10-day treatment with PNV or AMC. The risk of recurrence was lower with CPD.